Who is sponsoring NCT00313742?

NCT00313742 is sponsored by Novo Nordisk A/S.

What condition does NCT00313742 study?

NCT00313742 studies Diabetes, Diabetes Mellitus, Type 1.

What drugs are being tested in NCT00313742?

Interventions: insulin detemir, insulin glargine, insulin NPH.

What is the status of NCT00313742?

NCT00313742 is currently COMPLETED.

Last reviewed 2023-10-31 · How we verify

An Assessment of the Impact of Performing Physical Exercise on the Maximum Plasma Glucose Decline in Subjects With Type 1 Diabetes Managed on a Basal Bolus Insulin Regimen: A Comparison of 3 Basal Insulin Treatments - Insulin Detemir, Insulin Glargine and NPH Insulin

NCT00313742 Phase 4 COMPLETED

This trial is conducted in Europe. The aim of this research is to assess the impact of three basal (long-acting) insulin treatments on blood glucose levels in people with type 1 diabetes when performing physical exercise.

Details

Lead sponsor	Novo Nordisk A/S
Phase	Phase 4
Status	COMPLETED
Enrolment	51
Start date	2006-04
Completion	2006-11

Conditions

Diabetes
Diabetes Mellitus, Type 1

Interventions

insulin detemir
insulin glargine
insulin NPH

Primary outcomes

The difference between plasma glucose concentrations immediately pre-exercise and the minimum plasma glucose concentrations (nadir) in the period 0-150 min following exercise — following 4 weeks of treatment

Countries

Germany, United Kingdom